Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting

World News: . []

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, presented updated data from multiple ELZONRIS (tagraxofusp; SL-401) clinical trials at the 2018 ASH Annual Meeting. Presentations are now available on the Stemline website, , under the Scientific Presentations tab.

Ivan Bergstein, M.D., CEO of Stemline, commented “The ELZONRIS clinical presentations showcased at ASH demonstrate a broad clinical potential in a wide range of malignancies. In particular, we believe that our data in relapsed/refractory CMML and MF provides important clinical proof-of-concept in two indications with unmet medical need, and underscores just two of the many potential expansion opportunities that targeting CD123 offers. At ASH, we continued to ramp-up our disease awareness campaign for BPDCN ahead of the upcoming FDA decision on the ELZONRIS BLA. Also, our sales force is prepared and poised to launch ELZONRIS, should approval be obtained. In parallel, our clinical development team is moving forward with plans to expand efforts, including initiating one or more registration-directed trials in indications beyond BPDN, while also continuing to pursue novel entry points in CD123 acute myeloid leukemia (AML) and other malignancies.”

More news and information about Stemline Therapeutics, Inc.

Published By:

Globe Newswire: 12:00 GMT Thursday 6th December 2018

Published: .

Search for other references to "stemline" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us